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This study presents experimental evidence for the mediation of a behavioral effect of phencyclidine-like drugs by inhibition 
of neurotransmission at excitatory synapses utilizing N-methyl-aspartate (NMA) receptors by showing that DL-2-amino- 
5-phosphonovalerate, a selective NMA antagonist, produces phencyclidine-like catalepsy in pigeons. This finding suggests the 
possibility that other behavioral actions of phencyclidine-like substances may be mediated in a similar fashion. 
Phencyclidine (PCP), a major drug of abuse, 
has anesthetic actions and produces effects that 
resemble schizophrenia. The mechanism of 
action of PCP-like drugs has not been established, 
although specific binding sites in brain have been 
identified that appear to be pharmacologically 
r e l e v a n t  4"7"9. PCP-like drugs selectively antagon- 
ize excitation of spinal neurons by N-methyl- 
aspartate (NMA) 1"2. Therefore, the behavioral ef- 
fects of PCP-like drugs might result from reduced 
neurotransmission at excitatory synapses utilizing 
NMA receptors in higher centers of the central 
nervous system. Until now, this proposed explan- 
ation of the behavioral effects of PCP-like drugs 
is based exclusively on electrophysiological find- 
ings. In the present study, we have made an initial 
attempt to evaluate experimentally the possible 
involvement of NMA receptors in the mediation 
of behavioral actions of PCP-like drugs. 
If PCP-like drugs produce behavioral effects pri- 
marily through antagonism at excitatory synapses 
utilizing NMA receptors, drugs that are known to 
antagonize electrophysiological effects of NMA 
should produce PCP-like behavioral effects. 
DL-2-Amino-5-phosphonovalerate (AP5) is a po- 
tent and highly selective NMA antagonist 8. A 
procedure for the measurement of catalepsy in 
pigeons, suitable for studying PCP-like activity of 
compounds, has been described 5. PCP-induced 
catalepsy was shown to be pharmacologically 
specific and stereoselective, as evidenced by the 
observation that pentobarbital fails to induce 
catalepsy and that catalepsy is induced by the 
( + )-isomers but not by the ( - )-isomers of PCP- 
like drugs. The catalepsy test was used to investi- 
gate possible PCP-like effects of the NMA-anta- 
gonist, AP5. 
The subjects were 10 experimentally naive 
White Carneaux pigeons (weighing between 
450-550 g), which were housed individually, with 
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food and water freely available. A chronic, in- 
dwelling guide cannula was implanted under 
anesthesia with the tip directly into the lateral 
ventricle 3. Cannula patency was assessed by a 
radiographic method 3. Five pigeons were tested 
after intracerebroventricular (i.c.v.) injections 
(10/al/pigeon) of PCP (free base, dissolved in 
sterile water; pH 6-8;  Warner-Lambert/Parke- 
Davis, Ann Arbor). The other 5 pigeons were 
tested with AP5 (dissolved in 1 N NaOH, to 
which sterile water was added; pH 6-8;  Tocris 
Chemicals, Buckhurst Hill, England). Presence or 
absence of catalepsy (defined as loss of fighting, 
without head-drop and without eye closure) was 
assessed at successive time-intervals after each 
injection. Tests of different doses were separated 
by 48 h. 
Catalepsy was induced dose- and time-depen- 
dently by i.c.v, administration of PCP (Fig. 1, 
upper panels). AP5 produced catalepsy that had 
each of the signs of PCP-induced catalepsy noted 
above, and these effects were also dose- and time- 
dependent (Fig. 1, upper lefthand panel, lower 
panel). AP5 was more potent and had a longer 
duration of action than PCP. The mean threshold 
dose (average of the lowest dose which produced 
catalepsy at 15 min postinjection in each pigeon) 
of PCP was 2.7 + 0.4 (S.E.M.)#mol/pigeon 
(ca. 1.3 mg/kg). The mean threshold dose of PCP, 
when administered i.m., has been shown to be 
1.5 + 0.3 mg/kg 5, suggesting that PCP is equipo- 
tent when given i.c.v, or i.m. The mean threshold 
dose of AP5 was 0.5 + 0.2 #mol, about 5 times 
smaller than the mean threshold dose of PCP 
(Student's t = 4.17, df = 8, P < 0.01). The mean 
duration of catalepsy (average of duration of cata- 
lepsy in each pigeon) was 33 + 7min after 
4.1 #mol of PCP and was about 5 times longer 
(i.e. 183 + 83 min) after 1 #mol ofAP5 (t = 1.97, 
df = 8, P < 0.10). 
That AP5 had the capacity to produce catalep- 
sy of a form comparable to PCP was striking. This 
finding shows that a drug previously identified as 
an NMA antagonist appears to have PCP-like 
behavioral effects and adds behavioral evidence 
to the electrophysiological observations of a 
coincidence of PCP-agonist and NMA-an- 
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Fig. 1. Upper lefthand panel: dose-effect curves of AP5- and 
PCP-induced catalepsy (loss of righting without head-drop 
and without eye closure) in pigeons (n = 5 per drug) assessed 
15 min after i.c.v, administration. Ordinate: percentage of 
subjects showing catalepsy. Abscissa: dose administered. 
Upper righthand panel and lower panel: time-effect curves of 
PCP- and AP5-induced catalepsy at different dose levels. 
Ordinates: percentage of subjects showing catalepsy. Abscis- 
sae: time after injection. 
activity studies are necessary to study whether 
this PCP-like behavioral action of AP5 is depen- 
dent upon the NMA-antagonist properties of 
AP5. However, the present result makes viable 
the hypothesis stated above that catalepsy and, 
perhaps, other behavioral effects of PCP-like sub- 
stances, may be mediated by inhibition of neuro- 
transmission at excitatory synapses utilizing 
NMA receptors. There is a strong association 
between PCP-induced catalepsy in pigeons, PCP- 
like discriminative stimulus effects in pigeons 6, 
and PCP-like anesthesia. Therefore, NMA anta- 
gonists might have PCP-like anesthetic actions. 
Conversely, NMA agonists might antagonize be- 
havioral effects of PCP. 
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